Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review

被引：10

作者：

Amano, Tsukuru ^{[1
]}

Chano, Tokuhiro ^{[2
]}

Yoshino, Fumi ^{[1
]}

Kimura, Fuminori ^{[1
]}

Murakami, Takashi ^{[1
]}

机构：

[1] Shiga Univ Med Sci, Dept Obstet & Gynecol, Otsu, Shiga 5202192, Japan

[2] Shiga Univ Med Sci, Dept Clin Lab Med, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan

来源：

HEALTHCARE | 2019年 / 7卷 / 03期

关键词：

ovarian clear cell carcinoma; molecular therapeutic targets; immunotherapy; anti-PD-1; antibodies; anti-PD-L1; HEPATOCYTE NUCLEAR FACTOR-1-BETA; DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; EXPRESSION PROFILES; ARL4C EXPRESSION; PTEN EXPRESSION; GENE-EXPRESSION; PIK3CA MUTATION; CANCER; ENDOMETRIOSIS;

D O I：

10.3390/healthcare7030094

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Ovarian clear cell carcinoma (OCCC) shows low sensitivity to conventional chemotherapy and has a poor prognosis, especially in advanced stages. Therefore, the development of innovative therapeutic strategies and precision medicine for the treatment of OCCC are important. Recently, several new molecular targets have been identified for OCCC, which can be broadly divided into four categories: (a) downstream pathways of receptor tyrosine kinases, (b) anti-oxidative stress molecules, (c) AT-rich interactive domain 1A-related chromatin remodeling errors, and (d) anti-programmed death ligand 1/programmed cell death 1 agents. Several inhibitors have been discovered for these targets, and the suppression of OCCC cells has been demonstrated both in vitro and in vivo. However, no single inhibitor has shown a sufficient effectiveness in clinical pilot studies. This review outlines recent progress regarding the molecular biological characteristics of OCCC to identify future directions for the development of precision medicine and combinatorial therapies to treat OCCC.

引用

页数：12